Decibel Therapeutics (DBTX) Appoints Matthew Kapusta to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Google defeats US bid to force ad tech sale
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
March 21, 2023 7:01 AM EDTBOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors.
We are pleased to welcome Matt to the Decibel Board. He is an accomplished life sciences executive who has played a key role in advancing gene therapy products from the laboratory to patients in need, said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. Matts appointment to the Board provides... More
